{
    "ticker": "ARWR",
    "name": "Arrowhead Pharmaceuticals, Inc.",
    "description": "Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing transformative medicines for patients with genetically validated diseases. Founded in 2008 and headquartered in Pasadena, California, Arrowhead leverages its proprietary Targeted RNAi Molecule (TRiMTM) platform to design and develop therapies that can intervene in disease processes at the genetic level. The company's lead product candidate, ARO-HBV, is aimed at treating chronic hepatitis B virus infections, and it has several other candidates in various stages of clinical development targeting diseases such as alpha-1 antitrypsin deficiency and cardiovascular diseases. Arrowhead is committed to advancing the field of RNA interference (RNAi) therapeutics, which has the potential to provide innovative treatment options for a range of serious diseases. With a robust pipeline and strong intellectual property portfolio, Arrowhead is positioned to make a significant impact in the biopharmaceutical industry, aiming to improve the lives of patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Pasadena, California, USA",
    "founded": "2008",
    "website": "https://www.arrowheadpharma.com",
    "ceo": "Christopher Anzalone",
    "social_media": {
        "twitter": "https://twitter.com/ArrowheadPharma",
        "linkedin": "https://www.linkedin.com/company/arrowhead-pharmaceuticals/"
    },
    "investor_relations": "https://ir.arrowheadpharma.com",
    "key_executives": [
        {
            "name": "Christopher Anzalone",
            "position": "CEO"
        },
        {
            "name": "William S. Marshall",
            "position": "President"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ARO-HBV",
                "ARO-AAT",
                "ARO-APOC3"
            ]
        }
    ],
    "seo": {
        "meta_title": "Arrowhead Pharmaceuticals, Inc. | Transformative RNAi Medicines",
        "meta_description": "Learn about Arrowhead Pharmaceuticals, Inc., a leader in RNAi therapeutics. Explore their innovative product pipeline and commitment to treating genetic diseases.",
        "keywords": [
            "Arrowhead Pharmaceuticals",
            "RNAi",
            "Therapeutics",
            "Biotechnology",
            "Chronic Hepatitis B",
            "Genetic Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does Arrowhead Pharmaceuticals specialize in?",
            "answer": "Arrowhead Pharmaceuticals specializes in developing RNA interference (RNAi) therapeutics for genetically validated diseases."
        },
        {
            "question": "Who is the CEO of Arrowhead Pharmaceuticals?",
            "answer": "Christopher Anzalone is the CEO of Arrowhead Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Arrowhead Pharmaceuticals headquartered?",
            "answer": "Arrowhead Pharmaceuticals is headquartered in Pasadena, California, USA."
        },
        {
            "question": "What are some of Arrowhead's product candidates?",
            "answer": "Arrowhead's product candidates include ARO-HBV for hepatitis B, ARO-AAT for alpha-1 antitrypsin deficiency, and ARO-APOC3 for lowering triglyceride levels."
        },
        {
            "question": "When was Arrowhead Pharmaceuticals founded?",
            "answer": "Arrowhead Pharmaceuticals was founded in 2008."
        }
    ],
    "competitors": [
        "ALNY",
        "IONQ",
        "REGN",
        "SNY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}